Results 11 to 20 of about 326,443 (336)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients [PDF]

BMC Cancer, 2022
Abstract Background Human epidermal growth factor receptor 2 (HER2)-positive tumors are defined by protein overexpression (3+) or gene amplification using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), respectively.
Yoshiya Horimoto, Yumiko Ishizuka, Yuko Ueki, Toru Higuchi, Atsushi Arakawa, Mitsue Saito   +5 more
openaire   +3 more sources

Bone metastases of breast cancer: The influence of hormone receptors and human epidermal growth factor receptor 2 [PDF]

Medicinski Podmladak
Breast cancer is the leading cause of cancer-related deaths among women worldwide. While significant progress has been made in the prophylaxis, diagnosis, and management of breast cancer, around 90% of deaths occur due to metastatic disease, which is ...
Rajković Stanislav, Sopta Jelena
doaj   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study

European Journal of Breast Health, 2022
Objective:Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy ...
Damiano Gentile, Andrea Sagona, Ruggero Spoto, Davide Franceschini, Stefano Vaccari, Valeriano Vinci, Ersilia Biondi, Lorenzo Scardina, Corrado Tinterri   +8 more
doaj   +1 more source

Clinical and molecular characterization of HER2 amplified-pancreatic cancer [PDF]

, 2013
<p>Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome ...
Biankin, A.V., Chang, D.K., Chantrill, L., Chin, V., Chou, A., Cowley, M.J., Gill, A.J., Goldstein, D., Grimmond, S.M., Humphris, J., Johns, A.L., Kassahn, K.S., Mead, R., Miller, D.K., Morey, A.L., Musgrove, E.A., Nagrial, A.M., Nones, K., Pajic, M., Patch, A.M., Pearson, J.V., Pinese, M., Rooman, I., Samra, J.S., Toon, C.W., Waddell, N., Wasan, H., Wu, J.   +27 more
core   +3 more sources

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

Exploration of Targeted Anti-tumor Therapy, 2021
About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene.
Paolo Tarantino, Stefania Morganti, Giuseppe Curigliano   +2 more
doaj   +1 more source

Afatinib use in recurrent epithelial ovarian carcinoma. [PDF]

, 2019
•Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies.•Targetable mutations may lead to new therapies in gynecologic cancer treatment.•Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 ...
Alvarez, Edwin A, Hanft, Wyatt J, Kennedy, Vanessa A, Shepherd-Littlejohn, Amanda L   +3 more
core   +1 more source

HER2 overexpression is a putative diagnostic and prognostic biomarker for late-stage colorectal cancer in North African patients

Libyan Journal of Medicine, 2021
Aim: Colorectal cancer (CRC) is one of the leading cancers in the world. Even though its mortality and pathophysiology are well documented in the US and the European countries, it is seldom studied in North African population.
Eman A. Abdul Razzaq, Thenmozhi Venkatachalam, Khuloud Bajbouj, Mohamed Rahmani, Amena Mahdami, Surendra Rawat, Naziha Mansuri, Hussein Alhashemi, Rifat Akram Hamoudi, Riyad Bendardaf   +9 more
doaj   +1 more source

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

陆军军医大学学报, 2022
Objective To analyze the efficacy and safety of different treatments in advanced lung adenocarcinoma patients with v-raf murine sarcoma viral oncogene homolog B1(BRAF) BRAF V600E mutation, human epidermal growth factor receptor 2 (HER2) mutation ...
LIN Qingyue, QU Jingjing, ZHOU Jianying
doaj   +1 more source

Calmodulin binds HER2 and modulates HER2 signaling

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
Human epidermal growth factor receptor 2 (HER2), a member of the ErbB family of receptor tyrosine kinases, has defined roles in neoplastic transformation and tumor progression. Overexpression of HER2 is an adverse prognostic factor in several human neoplasms and, particularly in breast cancer, correlates strongly with a decrease in overall patient ...
White, Colin D., Li, Zhigang, Sacks, David B.   +2 more
openaire   +2 more sources